カテゴリ： 世界, 医療/バイオ, Market Monitor Global

IBS-C治療薬のグローバル市場展望 2023年-2029年：リナクロチド、ルビプロストン、浸透圧性下剤、刺激性下剤、その他

■ 英語タイトル：IBS-C Drugs Market, Global Outlook and Forecast 2023-2029

調査会社Market Monitor Global社が発行したリサーチレポート（データ管理コード：MMG23LY8794）■ 発行会社/調査会社：Market Monitor Global
■ 商品コード：MMG23LY8794
■ 発行日：2023年7月
■ 調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
■ 産業分野：医薬品＆ヘルスケア
■ ページ数：123
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Market Monitor Global社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[IBS-C治療薬のグローバル市場展望 2023年-2029年：リナクロチド、ルビプロストン、浸透圧性下剤、刺激性下剤、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査レポートは次の情報を含め、世界のIBS-C治療薬市場規模と予測を収録しています。・世界のIBS-C治療薬市場：売上、2018年-2023年、2024年-2029年
・世界のIBS-C治療薬市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界のIBS-C治療薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「リナクロチド」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

IBS-C治療薬のグローバル主要企業は、Catalent Pharmaceuticals Solutions、 Nestle、 Abbott Laboratories、 Synergy Pharmaceuticals、 Sucampo Pharmaceuticals、 Novartis Pharma Ag、 Astellas Pharmaceuticals、 Ardelyx, Inc、 Synthetic Biologics, Inc、 Teva Pharmaceutical Industries、 Bama-Geve, SLU、 Ferring BV、 Ironwood Pharmaceuticals, Inc、 Salix Pharmaceuticals Ltd、 Norgine B.V、 Prometheus Laboratories Inc、 Actavis Nordic A/S、 Albireo Pharma Inc、 Yuhan Corp、 Astrazeneca Plc、 The Menarini Group、 Ono Pharmaceutical Co., Ltdなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、IBS-C治療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界のIBS-C治療薬市場：タイプ別、2018年-2023年、2024年-2029年
世界のIBS-C治療薬市場：タイプ別市場シェア、2022年
・リナクロチド、ルビプロストン、浸透圧性下剤、刺激性下剤、その他

世界のIBS-C治療薬市場：用途別、2018年-2023年、2024年-2029年
世界のIBS-C治療薬市場：用途別市場シェア、2022年
・病院薬局、小売薬局、オンライン薬局

世界のIBS-C治療薬市場：地域・国別、2018年-2023年、2024年-2029年
世界のIBS-C治療薬市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業におけるIBS-C治療薬のグローバル売上、2018年-2023年
・主要企業におけるIBS-C治療薬のグローバル売上シェア、2022年
・主要企業におけるIBS-C治療薬のグローバル販売量、2018年-2023年
・主要企業におけるIBS-C治療薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Catalent Pharmaceuticals Solutions、 Nestle、 Abbott Laboratories、 Synergy Pharmaceuticals、 Sucampo Pharmaceuticals、 Novartis Pharma Ag、 Astellas Pharmaceuticals、 Ardelyx, Inc、 Synthetic Biologics, Inc、 Teva Pharmaceutical Industries、 Bama-Geve, SLU、 Ferring BV、 Ironwood Pharmaceuticals, Inc、 Salix Pharmaceuticals Ltd、 Norgine B.V、 Prometheus Laboratories Inc、 Actavis Nordic A/S、 Albireo Pharma Inc、 Yuhan Corp、 Astrazeneca Plc、 The Menarini Group、 Ono Pharmaceutical Co., Ltd

*************************************************************

・調査・分析レポートの概要
IBS-C治療薬市場の定義
市場セグメント
世界のIBS-C治療薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界のIBS-C治療薬市場規模
世界のIBS-C治療薬市場規模：2022年 VS 2029年
世界のIBS-C治療薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでのIBS-C治療薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業のIBS-C治療薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：リナクロチド、ルビプロストン、浸透圧性下剤、刺激性下剤、その他
IBS-C治療薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院薬局、小売薬局、オンライン薬局
IBS-C治療薬の用途別グローバル売上・予測

・地域別市場分析
地域別IBS-C治療薬市場規模 2022年と2029年
地域別IBS-C治療薬売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Catalent Pharmaceuticals Solutions、 Nestle、 Abbott Laboratories、 Synergy Pharmaceuticals、 Sucampo Pharmaceuticals、 Novartis Pharma Ag、 Astellas Pharmaceuticals、 Ardelyx, Inc、 Synthetic Biologics, Inc、 Teva Pharmaceutical Industries、 Bama-Geve, SLU、 Ferring BV、 Ironwood Pharmaceuticals, Inc、 Salix Pharmaceuticals Ltd、 Norgine B.V、 Prometheus Laboratories Inc、 Actavis Nordic A/S、 Albireo Pharma Inc、 Yuhan Corp、 Astrazeneca Plc、 The Menarini Group、 Ono Pharmaceutical Co., Ltd
...

This report aims to provide a comprehensive presentation of the global market for IBS-C Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding IBS-C Drugs. This report contains market size and forecasts of IBS-C Drugs in global, including the following market information:
Global IBS-C Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global IBS-C Drugs Market Sales, 2018-2023, 2024-2029, (K Pcs)
Global top five IBS-C Drugs companies in 2022 (%)
The global IBS-C Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Linaclotide Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of IBS-C Drugs include Catalent Pharmaceuticals Solutions, Nestle, Abbott Laboratories, Synergy Pharmaceuticals, Sucampo Pharmaceuticals, Novartis Pharma Ag, Astellas Pharmaceuticals, Ardelyx, Inc and Synthetic Biologics, Inc, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the IBS-C Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global IBS-C Drugs Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global IBS-C Drugs Market Segment Percentages, by Type, 2022 (%)
Linaclotide
Lubiprostone
Osmotic Laxatives
Stimulant Laxatives
Others
Global IBS-C Drugs Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global IBS-C Drugs Market Segment Percentages, by Application, 2022 (%)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global IBS-C Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global IBS-C Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies IBS-C Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies IBS-C Drugs revenues share in global market, 2022 (%)
Key companies IBS-C Drugs sales in global market, 2018-2023 (Estimated), (K Pcs)
Key companies IBS-C Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Catalent Pharmaceuticals Solutions
Nestle
Abbott Laboratories
Synergy Pharmaceuticals
Sucampo Pharmaceuticals
Novartis Pharma Ag
Astellas Pharmaceuticals
Ardelyx, Inc
Synthetic Biologics, Inc
Teva Pharmaceutical Industries
Bama-Geve, SLU
Ferring BV
Ironwood Pharmaceuticals, Inc
Salix Pharmaceuticals Ltd
Norgine B.V
Prometheus Laboratories Inc
Actavis Nordic A/S
Albireo Pharma Inc
Yuhan Corp
Astrazeneca Plc
The Menarini Group
Ono Pharmaceutical Co., Ltd
Outline of Major Chapters:
Chapter 1: Introduces the definition of IBS-C Drugs, market overview.
Chapter 2: Global IBS-C Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of IBS-C Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of IBS-C Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global IBS-C Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Introduction to Research & Analysis Reports
1.1 IBS-C Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global IBS-C Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global IBS-C Drugs Overall Market Size
2.1 Global IBS-C Drugs Market Size: 2022 VS 2029
2.2 Global IBS-C Drugs Revenue, Prospects & Forecasts: 2018-2029
2.3 Global IBS-C Drugs Sales: 2018-2029
3 Company Landscape
3.1 Top IBS-C Drugs Players in Global Market
3.2 Top Global IBS-C Drugs Companies Ranked by Revenue
3.3 Global IBS-C Drugs Revenue by Companies
3.4 Global IBS-C Drugs Sales by Companies
3.5 Global IBS-C Drugs Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 IBS-C Drugs Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers IBS-C Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 IBS-C Drugs Players in Global Market
3.8.1 List of Global Tier 1 IBS-C Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 IBS-C Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global IBS-C Drugs Market Size Markets, 2022 & 2029
4.1.2 Linaclotide
4.1.3 Lubiprostone
4.1.4 Osmotic Laxatives
4.1.5 Stimulant Laxatives
4.1.6 Others
4.2 By Type – Global IBS-C Drugs Revenue & Forecasts
4.2.1 By Type – Global IBS-C Drugs Revenue, 2018-2023
4.2.2 By Type – Global IBS-C Drugs Revenue, 2024-2029
4.2.3 By Type – Global IBS-C Drugs Revenue Market Share, 2018-2029
4.3 By Type – Global IBS-C Drugs Sales & Forecasts
4.3.1 By Type – Global IBS-C Drugs Sales, 2018-2023
4.3.2 By Type – Global IBS-C Drugs Sales, 2024-2029
4.3.3 By Type – Global IBS-C Drugs Sales Market Share, 2018-2029
4.4 By Type – Global IBS-C Drugs Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global IBS-C Drugs Market Size, 2022 & 2029
5.1.2 Hospital Pharmacies
5.1.3 Retail Pharmacies
5.1.4 Online Pharmacies
5.2 By Application – Global IBS-C Drugs Revenue & Forecasts
5.2.1 By Application – Global IBS-C Drugs Revenue, 2018-2023
5.2.2 By Application – Global IBS-C Drugs Revenue, 2024-2029
5.2.3 By Application – Global IBS-C Drugs Revenue Market Share, 2018-2029
5.3 By Application – Global IBS-C Drugs Sales & Forecasts
5.3.1 By Application – Global IBS-C Drugs Sales, 2018-2023
5.3.2 By Application – Global IBS-C Drugs Sales, 2024-2029
5.3.3 By Application – Global IBS-C Drugs Sales Market Share, 2018-2029
5.4 By Application – Global IBS-C Drugs Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global IBS-C Drugs Market Size, 2022 & 2029
6.2 By Region – Global IBS-C Drugs Revenue & Forecasts
6.2.1 By Region – Global IBS-C Drugs Revenue, 2018-2023
6.2.2 By Region – Global IBS-C Drugs Revenue, 2024-2029
6.2.3 By Region – Global IBS-C Drugs Revenue Market Share, 2018-2029
6.3 By Region – Global IBS-C Drugs Sales & Forecasts
6.3.1 By Region – Global IBS-C Drugs Sales, 2018-2023
6.3.2 By Region – Global IBS-C Drugs Sales, 2024-2029
6.3.3 By Region – Global IBS-C Drugs Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America IBS-C Drugs Revenue, 2018-2029
6.4.2 By Country – North America IBS-C Drugs Sales, 2018-2029
6.4.3 US IBS-C Drugs Market Size, 2018-2029
6.4.4 Canada IBS-C Drugs Market Size, 2018-2029
6.4.5 Mexico IBS-C Drugs Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe IBS-C Drugs Revenue, 2018-2029
6.5.2 By Country – Europe IBS-C Drugs Sales, 2018-2029
6.5.3 Germany IBS-C Drugs Market Size, 2018-2029
6.5.4 France IBS-C Drugs Market Size, 2018-2029
6.5.5 U.K. IBS-C Drugs Market Size, 2018-2029
6.5.6 Italy IBS-C Drugs Market Size, 2018-2029
6.5.7 Russia IBS-C Drugs Market Size, 2018-2029
6.5.8 Nordic Countries IBS-C Drugs Market Size, 2018-2029
6.5.9 Benelux IBS-C Drugs Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia IBS-C Drugs Revenue, 2018-2029
6.6.2 By Region – Asia IBS-C Drugs Sales, 2018-2029
6.6.3 China IBS-C Drugs Market Size, 2018-2029
6.6.4 Japan IBS-C Drugs Market Size, 2018-2029
6.6.5 South Korea IBS-C Drugs Market Size, 2018-2029
6.6.6 Southeast Asia IBS-C Drugs Market Size, 2018-2029
6.6.7 India IBS-C Drugs Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America IBS-C Drugs Revenue, 2018-2029
6.7.2 By Country – South America IBS-C Drugs Sales, 2018-2029
6.7.3 Brazil IBS-C Drugs Market Size, 2018-2029
6.7.4 Argentina IBS-C Drugs Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa IBS-C Drugs Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa IBS-C Drugs Sales, 2018-2029
6.8.3 Turkey IBS-C Drugs Market Size, 2018-2029
6.8.4 Israel IBS-C Drugs Market Size, 2018-2029
6.8.5 Saudi Arabia IBS-C Drugs Market Size, 2018-2029
6.8.6 UAE IBS-C Drugs Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Catalent Pharmaceuticals Solutions
7.1.1 Catalent Pharmaceuticals Solutions Company Summary
7.1.2 Catalent Pharmaceuticals Solutions Business Overview
7.1.3 Catalent Pharmaceuticals Solutions IBS-C Drugs Major Product Offerings
7.1.4 Catalent Pharmaceuticals Solutions IBS-C Drugs Sales and Revenue in Global (2018-2023)
7.1.5 Catalent Pharmaceuticals Solutions Key News & Latest Developments
7.2 Nestle
7.2.1 Nestle Company Summary
7.2.2 Nestle Business Overview
7.2.3 Nestle IBS-C Drugs Major Product Offerings
7.2.4 Nestle IBS-C Drugs Sales and Revenue in Global (2018-2023)
7.2.5 Nestle Key News & Latest Developments
7.3 Abbott Laboratories
7.3.1 Abbott Laboratories Company Summary
7.3.2 Abbott Laboratories Business Overview
7.3.3 Abbott Laboratories IBS-C Drugs Major Product Offerings
7.3.4 Abbott Laboratories IBS-C Drugs Sales and Revenue in Global (2018-2023)
7.3.5 Abbott Laboratories Key News & Latest Developments
7.4 Synergy Pharmaceuticals
7.4.1 Synergy Pharmaceuticals Company Summary
7.4.2 Synergy Pharmaceuticals Business Overview
7.4.3 Synergy Pharmaceuticals IBS-C Drugs Major Product Offerings
7.4.4 Synergy Pharmaceuticals IBS-C Drugs Sales and Revenue in Global (2018-2023)
7.4.5 Synergy Pharmaceuticals Key News & Latest Developments
7.5 Sucampo Pharmaceuticals
7.5.1 Sucampo Pharmaceuticals Company Summary
7.5.2 Sucampo Pharmaceuticals Business Overview
7.5.3 Sucampo Pharmaceuticals IBS-C Drugs Major Product Offerings
7.5.4 Sucampo Pharmaceuticals IBS-C Drugs Sales and Revenue in Global (2018-2023)
7.5.5 Sucampo Pharmaceuticals Key News & Latest Developments
7.6 Novartis Pharma Ag
7.6.1 Novartis Pharma Ag Company Summary
7.6.2 Novartis Pharma Ag Business Overview
7.6.3 Novartis Pharma Ag IBS-C Drugs Major Product Offerings
7.6.4 Novartis Pharma Ag IBS-C Drugs Sales and Revenue in Global (2018-2023)
7.6.5 Novartis Pharma Ag Key News & Latest Developments
7.7 Astellas Pharmaceuticals
7.7.1 Astellas Pharmaceuticals Company Summary
7.7.2 Astellas Pharmaceuticals Business Overview
7.7.3 Astellas Pharmaceuticals IBS-C Drugs Major Product Offerings
7.7.4 Astellas Pharmaceuticals IBS-C Drugs Sales and Revenue in Global (2018-2023)
7.7.5 Astellas Pharmaceuticals Key News & Latest Developments
7.8 Ardelyx, Inc
7.8.1 Ardelyx, Inc Company Summary
7.8.2 Ardelyx, Inc Business Overview
7.8.3 Ardelyx, Inc IBS-C Drugs Major Product Offerings
7.8.4 Ardelyx, Inc IBS-C Drugs Sales and Revenue in Global (2018-2023)
7.8.5 Ardelyx, Inc Key News & Latest Developments
7.9 Synthetic Biologics, Inc
7.9.1 Synthetic Biologics, Inc Company Summary
7.9.2 Synthetic Biologics, Inc Business Overview
7.9.3 Synthetic Biologics, Inc IBS-C Drugs Major Product Offerings
7.9.4 Synthetic Biologics, Inc IBS-C Drugs Sales and Revenue in Global (2018-2023)
7.9.5 Synthetic Biologics, Inc Key News & Latest Developments
7.10 Teva Pharmaceutical Industries
7.10.1 Teva Pharmaceutical Industries Company Summary
7.10.2 Teva Pharmaceutical Industries Business Overview
7.10.3 Teva Pharmaceutical Industries IBS-C Drugs Major Product Offerings
7.10.4 Teva Pharmaceutical Industries IBS-C Drugs Sales and Revenue in Global (2018-2023)
7.10.5 Teva Pharmaceutical Industries Key News & Latest Developments
7.11 Bama-Geve, SLU
7.11.1 Bama-Geve, SLU Company Summary
7.11.2 Bama-Geve, SLU IBS-C Drugs Business Overview
7.11.3 Bama-Geve, SLU IBS-C Drugs Major Product Offerings
7.11.4 Bama-Geve, SLU IBS-C Drugs Sales and Revenue in Global (2018-2023)
7.11.5 Bama-Geve, SLU Key News & Latest Developments
7.12 Ferring BV
7.12.1 Ferring BV Company Summary
7.12.2 Ferring BV IBS-C Drugs Business Overview
7.12.3 Ferring BV IBS-C Drugs Major Product Offerings
7.12.4 Ferring BV IBS-C Drugs Sales and Revenue in Global (2018-2023)
7.12.5 Ferring BV Key News & Latest Developments
7.13 Ironwood Pharmaceuticals, Inc
7.13.1 Ironwood Pharmaceuticals, Inc Company Summary
7.13.2 Ironwood Pharmaceuticals, Inc IBS-C Drugs Business Overview
7.13.3 Ironwood Pharmaceuticals, Inc IBS-C Drugs Major Product Offerings
7.13.4 Ironwood Pharmaceuticals, Inc IBS-C Drugs Sales and Revenue in Global (2018-2023)
7.13.5 Ironwood Pharmaceuticals, Inc Key News & Latest Developments
7.14 Salix Pharmaceuticals Ltd
7.14.1 Salix Pharmaceuticals Ltd Company Summary
7.14.2 Salix Pharmaceuticals Ltd Business Overview
7.14.3 Salix Pharmaceuticals Ltd IBS-C Drugs Major Product Offerings
7.14.4 Salix Pharmaceuticals Ltd IBS-C Drugs Sales and Revenue in Global (2018-2023)
7.14.5 Salix Pharmaceuticals Ltd Key News & Latest Developments
7.15 Norgine B.V
7.15.1 Norgine B.V Company Summary
7.15.2 Norgine B.V Business Overview
7.15.3 Norgine B.V IBS-C Drugs Major Product Offerings
7.15.4 Norgine B.V IBS-C Drugs Sales and Revenue in Global (2018-2023)
7.15.5 Norgine B.V Key News & Latest Developments
7.16 Prometheus Laboratories Inc
7.16.1 Prometheus Laboratories Inc Company Summary
7.16.2 Prometheus Laboratories Inc Business Overview
7.16.3 Prometheus Laboratories Inc IBS-C Drugs Major Product Offerings
7.16.4 Prometheus Laboratories Inc IBS-C Drugs Sales and Revenue in Global (2018-2023)
7.16.5 Prometheus Laboratories Inc Key News & Latest Developments
7.17 Actavis Nordic A/S
7.17.1 Actavis Nordic A/S Company Summary
7.17.2 Actavis Nordic A/S Business Overview
7.17.3 Actavis Nordic A/S IBS-C Drugs Major Product Offerings
7.17.4 Actavis Nordic A/S IBS-C Drugs Sales and Revenue in Global (2018-2023)
7.17.5 Actavis Nordic A/S Key News & Latest Developments
7.18 Albireo Pharma Inc
7.18.1 Albireo Pharma Inc Company Summary
7.18.2 Albireo Pharma Inc Business Overview
7.18.3 Albireo Pharma Inc IBS-C Drugs Major Product Offerings
7.18.4 Albireo Pharma Inc IBS-C Drugs Sales and Revenue in Global (2018-2023)
7.18.5 Albireo Pharma Inc Key News & Latest Developments
7.19 Yuhan Corp
7.19.1 Yuhan Corp Company Summary
7.19.2 Yuhan Corp Business Overview
7.19.3 Yuhan Corp IBS-C Drugs Major Product Offerings
7.19.4 Yuhan Corp IBS-C Drugs Sales and Revenue in Global (2018-2023)
7.19.5 Yuhan Corp Key News & Latest Developments
7.20 Astrazeneca Plc
7.20.1 Astrazeneca Plc Company Summary
7.20.2 Astrazeneca Plc Business Overview
7.20.3 Astrazeneca Plc IBS-C Drugs Major Product Offerings
7.20.4 Astrazeneca Plc IBS-C Drugs Sales and Revenue in Global (2018-2023)
7.20.5 Astrazeneca Plc Key News & Latest Developments
7.21 The Menarini Group
7.21.1 The Menarini Group Company Summary
7.21.2 The Menarini Group Business Overview
7.21.3 The Menarini Group IBS-C Drugs Major Product Offerings
7.21.4 The Menarini Group IBS-C Drugs Sales and Revenue in Global (2018-2023)
7.21.5 The Menarini Group Key News & Latest Developments
7.22 Ono Pharmaceutical Co., Ltd
7.22.1 Ono Pharmaceutical Co., Ltd Company Summary
7.22.2 Ono Pharmaceutical Co., Ltd Business Overview
7.22.3 Ono Pharmaceutical Co., Ltd IBS-C Drugs Major Product Offerings
7.22.4 Ono Pharmaceutical Co., Ltd IBS-C Drugs Sales and Revenue in Global (2018-2023)
7.22.5 Ono Pharmaceutical Co., Ltd Key News & Latest Developments
8 Global IBS-C Drugs Production Capacity, Analysis
8.1 Global IBS-C Drugs Production Capacity, 2018-2029
8.2 IBS-C Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global IBS-C Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 IBS-C Drugs Supply Chain Analysis
10.1 IBS-C Drugs Industry Value Chain
10.2 IBS-C Drugs Upstream Market
10.3 IBS-C Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 IBS-C Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • イボシデニブ薬のグローバル市場展望 2023年-2029年：60錠、30錠
  • ポナチニブ薬のグローバル市場展望 2023年-2029年：45mg、15mg
  • 長鎖ペプチド医薬品のグローバル市場展望 2023年-2029年：ホルモンペプチド製剤、免疫調節ペプチド製剤、血管作動性ペプチド製剤、その他
  • 口腔乾燥症治療薬のグローバル市場展望 2023年-2029年：スプレー、内服液、口腔錠、マウスウォッシュ
  • 皮膚糸状菌症治療薬のグローバル市場展望 2023年-2029年：Rx、OTC
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(MMG23LY8794 )"IBS-C治療薬のグローバル市場展望 2023年-2029年：リナクロチド、ルビプロストン、浸透圧性下剤、刺激性下剤、その他" (英文：IBS-C Drugs Market, Global Outlook and Forecast 2023-2029)はMarket Monitor Global社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。